Evidence map›Paper›PMID 20695009›Full record

ArticleAnnals of neurology2010

Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein.

Wen-Quan Zou, Gianfranco Puoti, Xiangzhu Xiao, Jue Yuan, Liuting Qing, Ignazio Cali, Miyuki Shimoji, Jan P M Langeveld, Rudy Castellani, Silvio Notari and 19 more

Open access · greenAbstract read
In one paragraph

Article in Annals of neurology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 286 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Prevalence and impact of comorbidities in amyotrophic lateral sclerosis.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Inducers and modulators of protein aggregation in Alzheimer's disease - Critical tools for understanding the foundations of aggregate structures.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Anxiety in oncology outpatients is associated with perturbations in pathways identified in anxiety focused network pharmacology research.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Article
  18. Article
  19. Review
  20. Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 14 institutions in 3 countries.

Wen-Quan ZouDepartment of Pathology, National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH 44106, USA. wenquan.zou@case.edu
Gianfranco Puoti
Xiangzhu Xiao
Jue Yuan
Liuting Qing
Ignazio Cali
Miyuki Shimoji
Jan P M Langeveld
Rudy Castellani
Silvio Notari
Barbara Crain
Robert E Schmidt
Michael Geschwind
Stephen J Dearmond
Nigel J Cairns
Dennis Dickson
Lawrence Honig
Juan Maria Torres
James Mastrianni
Sabina Capellari
Giorgio Giaccone
Ermias D Belay
Lawrence B Schonberger
Mark Cohen
George Perry
Qingzhong Kong
Piero Parchi
Fabrizio Tagliavini
Pierluigi Gambetti
Case Western Reserve University · USCenters for Disease Control and Prevention · USFondazione IRCCS Istituto Neurologico Carlo Besta · ITUniversity of Bologna · ITUniversity of California, San Francisco · USWashington University in St. Louis · USCentro de Investigación en Sanidad AnimalJohns Hopkins University · USMayo Clinic in Florida · USNewYork–Presbyterian Hospital · USThe University of Texas at San Antonio · USUniversity of Chicago · USUniversity of Maryland Medical Center · USWageningen University & Research · NL

Funding

WASHINGTON UNIVERSITY ALZHEIMERS DISEASE RESEARCH CENTERP50AG005681 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 1985 to 2019
$52.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
TRANSGENIC MODELS OF PRION DISEASES LINKED TO D178N MUTATIONP01AG014359 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI GAMBETTI, PIERLUIGI · 1997 to 2013
$22.2M
Predicting progression of human prion diseaseR01AG031189 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GESCHWIND, MICHAEL D · 2008 to 2017
$5.7M
Pathogenicity of prion protein aggregates from uninfected cells and brainsR01NS062787 · NINDS · CASE WESTERN RESERVE UNIVERSITY · PI ZOU, WEN-QUAN · 2009 to 2013
$1.4M
NIA NIH HHS AG05681NIA NIH HHS AG08702NIA NIH HHS AG14359NIA NIH HHS P01 AG014359NIA NIH HHS P50 AG005681NIA NIH HHS P50 AG008702NIA NIH HHS R01 AG031189NINDS NIH HHS R01 NS062787NINDS NIH HHS R01NS062787PHS HHS CCU 515004
6 · The paper itself

Abstract

objectiveThe objective of the study is to report 2 new genotypic forms of protease-sensitive prionopathy (PSPr), a novel prion disease described in 2008, in 11 subjects all homozygous for valine at codon 129 of the prion protein (PrP) gene (129VV). The 2 new PSPr forms affect individuals who are either homozygous for methionine (129MM) or heterozygous for methionine/valine (129MV).

methodsFifteen affected subjects with 129MM, 129MV, and 129VV underwent comparative evaluation at the National Prion Disease Pathology Surveillance Center for clinical, histopathologic, immunohistochemical, genotypical, and PrP characteristics.

resultsDisease duration (between 22 and 45 months) was significantly different in the 129VV and 129MV subjects. Most other phenotypic features along with the PrP electrophoretic profile were similar but distinguishable in the 3 129 genotypes. A major difference laid in the sensitivity to protease digestion of the disease-associated PrP, which was high in 129VV but much lower, or altogether lacking, in 129MV and 129MM. This difference prompted the substitution of the original designation with "variably protease-sensitive prionopathy" (VPSPr). None of the subjects had mutations in the PrP gene coding region.

interpretationBecause all 3 129 genotypes are involved, and are associated with distinguishable phenotypes, VPSPr becomes the second sporadic prion protein disease with this feature after Creutzfeldt-Jakob disease, originally reported in 1920. However, the characteristics of the abnormal prion protein suggest that VPSPr is different from typical prion diseases, and perhaps more akin to subtypes of Gerstmann-Sträussler-Scheinker disease.

Indexed as

Genetic VariationAdultAgedAged, 80 and overBrainDementiaDNA Mutational AnalysisFemaleGenetic TestingHumansMaleMiddle AgedPeptide HydrolasesPhenotypePrion DiseasesPrionsPeptide HydrolasesPrions

Identifiers

PMID20695009
PMCPMC3032610
OpenAlexW2170314199

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.